Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Arthritis, Rheumatoid 19Spondylitis, Ankylosing 6Psoriasis 4Colitis, Ulcerative 4Crohn Disease 3Inflammatory Bowel Diseases 2Uveal Melanoma 1Thyroid Carcinoma, Anaplastic 1Spondylarthritis 1Sarcoidosis 1Recurrence 1Plaque Psoriasis 1Osteoarthritis 1Nephrotic Syndrome 1Nephrosis, Lipoid 1Mucopolysaccharidosis VI 1Mucopolysaccharidosis II 1Mucopolysaccharidosis I 1Mucopolysaccharidoses 1Melanoma 1Macular dystrophy, corneal type 1 1Kidney Diseases 1Joint Diseases 1Inflammation 1Infections 1Hidradenitis Suppurativa 1Healthy Adult Male 1Healthy 1Glomerulosclerosis, Focal Segmental 1Dupuytren Contracture 1

Interventions

Adalimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Healthy Adult Male × Adalimumab × Clear all
NCT07181694 2025-10-03

A Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-057 100 mg/mL, BCD-057 50 mg/mL, and Humira 100 mg/mL in Healthy Subjects

Biocad

Phase 1 Recruiting
444 enrolled

Healthy Adult Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡